Literature DB >> 12093432

Measurement of body fat by dual-energy X-ray absorptiometry and bioimpedance analysis in men with prostate cancer.

Matthew R Smith1, Vanessa Fuchs, Ellen J Anderson, Mary Anne Fallon, Judith Manola.   

Abstract

OBJECTIVE: The aims of this study were to determine the percentage of body fat (%BF) by dual-energy x-ray absorptiometry (DXA) and bioelectrical impedance analysis (BIA) using a standard adult equation and BIA using a standard geriatric equation in a population of older men with prostate cancer and to compare the results from these different methods.
METHODS: We conducted a cross-sectional study in 38 men with locally advanced, node-positive, or recurrent prostate cancer and no history of androgen-deprivation therapy. Body composition was evaluated by DXA with the use of a Hologic 4500A densitometer and BIA. BIA %BF was calculated by using standard equations developed for adult and geriatric populations.
RESULTS: %BF by DXA, BIA with the standard adult equation, BIA with the standard geriatric equation, and BIA with the age-appropriate equation were 26.7 +/- 5.3%, 22.5 +/- 5.6%, 38.2 +/- 6.9%, and 35.4 +/- 9.6%, respectively. There were statistically significant differences between %BF by DXA and all BIA estimates. By using the methods described by Bland and Altman (Lancet 1986;1(8476):307), the standard adult equation showed the least bias and variability.
CONCLUSIONS: In this group of men with prostate cancer, BIA with the standard adult equation provided a reasonable estimate of %BF compared with DXA, although the differences were statistically significant. BIA with the standard geriatric equation, however, markedly overestimated %BF compared with DXA, even when its use was restricted to elderly men.

Entities:  

Mesh:

Year:  2002        PMID: 12093432     DOI: 10.1016/s0899-9007(02)00821-3

Source DB:  PubMed          Journal:  Nutrition        ISSN: 0899-9007            Impact factor:   4.008


  2 in total

Review 1.  Bioelectrical impedance analysis to estimate body composition in surgical and oncological patients: a systematic review.

Authors:  E B Haverkort; P L M Reijven; J M Binnekade; M A E de van der Schueren; C P Earthman; D J Gouma; R J de Haan
Journal:  Eur J Clin Nutr       Date:  2014-10-01       Impact factor: 4.016

2.  A randomized, double-blind, placebo-controlled trial of a beta-hydroxyl beta-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122).

Authors:  Lawrence Berk; Jennifer James; Anna Schwartz; Eugen Hug; Anand Mahadevan; Michael Samuels; Lisa Kachnic
Journal:  Support Care Cancer       Date:  2008-02-22       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.